Consumers take the offensive against J&J for Tylenol recalls

A constant supply of bad news is jeopardizing the long-term sales of Tylenol and other Johnson & Johnson (NYSE: JNJ) products, says Motley Fool columnist Brian Orelli. "Contrary to the popular saying, there is such a thing as bad press and if you're getting it month after month, it's even worse." If J&J can't overcome the negative image quickly, he says, consumers will head to competing brand-name drugs or just grab generics. They also make take more direct action: Consumers are accusing the drugmaker of fraud and racketeering in a lawsuit stemming from the recent recall, and demanding cash refunds rather than replacement coupons. Column | Article

Suggested Articles

Popular logic says you never switch horses, or CDMOs, in the middle of the stream, but Acacia Pharma had to do that to win an FDA approval.

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

A warning letter says Chinese API maker Yibin Lihao Bio-technical was found lying to the FDA about manufacturing unapproved heparin.